Month: October 2026

TORONTO, Oct. 29, 2026 (GLOBE NEWSWIRE) — Mink Ventures Corporation (TSXV:MINK) (“Mink” or the “Company“) today announced a non-brokered private placement for aggregate gross proceeds of up to $750,000 (the “Offering”). The Offering will consist of the sale of hard dollar units (the “HD Units”) of the Company at a price of $0.08 per HD Unit and flow-through units (the “FT Units”) of the Company at a price of $0.105 per FT Unit.

The Company plans to use the net proceeds raised from the sale of the HD Units and FT Units under the Offering for the exploration, drilling, and advancement of its 115 km² critical minerals project portfolio located within the prolific Timmins Camp. All programs are permitted and, subject to funding, include; conducting VTEM at its Montcalm nickel (Ni), copper (Cu), cobalt (Co) project, diamond drilling at its Warren Cu Ni project and the Rankin Cu Ni project and, in respect of the HD Unit proceeds, for general working capital purposes.

Each HD Unit will consist of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (“Warrant”). Each Warrant shall entitle the holder thereof to acquire one (1) common share of the Company for a period of thirty-six (36) months from the date of issuance at an exercise price of $0.16.

Each FT Unit will consist of one Common Share of the Company to be issued as a “flow-through share” (a “FT Share”) and one Common Share purchase warrant (“FT Warrant”). Each FT Warrant shall entitle the holder thereof to acquire one (1) common share of the Company for a period of thirty-six (36) months from the date of issuance at an exercise price of $0.16.

The FT Shares are to be issued as “flow-through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act”). An amount equal to the portion of the subscription price that is directly attributable to the consideration paid for the subscription and issuance of the FT Shares will be used to incur eligible resource exploration expenses which will qualify as (i) “Canadian exploration expenses” (as defined in the Tax Act), and (ii) “flow-through critical mineral mining expenditures” (as defined in subsection 127(9) of the Tax Act) (collectively, the “Qualifying Expenditures“). Qualifying Expenditures in an aggregate amount equal to the gross proceeds raised from the issuance of the FT Shares will be renounced to the initial purchasers of the FT Units with an effective date no later than December 31, 2026. The FT Warrants are not being issued as “flow-through shares” within the meaning of the Tax Act.

The securities issued under the Offering will be subject to a four-month and one day hold period and will not be sold in the United States. The Offering is subject to customary closing conditions including, but not limited to, receipt of approval of the TSX Venture Exchange (the “TSX-V”). The closing of the Offering may occur in one or more tranches, with the initial closing date of the Offering expected to occur on or around November 17, 2026 and is not subject to receipt of a minimum amount of gross proceeds. The Company may pay to certain introducing parties in respect of the Offering finder’s fees of up to 8% cash and non-transferable common share purchase warrants (“Finder Warrants”) to acquire that number of common shares equal to 8% of the number of HD Units and FT Units sold to investors so introduced, subject to compliance with applicable securities legislation and TSX-V policies. Each Finder Warrant shall entitle the holder thereof to acquire one (1) common share of the Company for a period of thirty-six (36) months from the date of issuance at an exercise price of $0.16.

About Mink Ventures Corporation:
Mink Ventures Corporation (TSXV:MINK) is a Canadian mineral exploration company exploring for critical minerals in Ontario, Canada. It has a prospective, nickel copper cobalt exploration portfolio, with its Montcalm project, which now covers approximately 100 km² adjacent to Glencore’s former Montcalm Mine with historical production of 3.93 million tonnes of ore grading 1.25% Ni, 0.67% Cu, and 0.051% Co (Ontario Geological Survey, Atkinson, 2010), as well as the expanded 11.3km² Warren Project, and its newly acquired Rankin Cu Ni project. These complementary nickel copper cobalt projects have excellent road access and infrastructure and are in close proximity to the Timmins Mining Camp. The Company has 41,672,296 common shares outstanding.

For further information about Mink Ventures Corporation please contact: Natasha Dixon, President & CEO, T: 250-882-5620 E: ndixon@minkventures.com or Kevin Filo, Director, T: 705-266-6818 or visit www.sedarplus.ca

Forward Looking Statements
This press release includes certain “forward-looking statements” under applicable Canadian securities legislation, including, but not limited to, statements with respect to the completion of the Offering, the proposed use of proceeds, and the exploration potential of the Company’s mineral properties. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Mink to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and factors include, among others: future prices and the supply of metals; the results of drilling; inability to raise the money necessary to incur the expenditures required to retain and advance the properties; environmental liabilities (known and unknown); general business, economic, competitive, political and social uncertainties; accidents, labour disputes and other risks of the mining industry; political instability, terrorism, insurrection or war; delays in obtaining governmental approvals; or failure to obtain regulatory approvals. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to Mink’s filings with Canadian securities regulators available on SEDAR+ at www.sedarplus.ca.

Although Mink has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this news release and Mink disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

Topsoe continues to deliver engineering materials on schedule and on budget, 
advancing integrated FEED for production of sustainable aviation fuel,
renewable diesel and chemicals

HOUSTON, TX, Oct. 29, 2026 (GLOBE NEWSWIRE) — Abundia Global Impact Group, Inc. (NYSE American: AGIG) (“Abundia” or the “Company”), today provided an update on the previously announced engineering partnership with Topsoe using their HydroFlex^® upgrading technology for the Company’s first waste plastics-to-renewable fuels and chemicals facility at Cedar Port.

“We are pleased to provide shareholders with an update on the continued progress the Company has made over recent months on its engineering pack and to highlight Topsoe’s consistent delivery of critical information as we progress our Cedar Port facility toward commercialization,” said Joseph Gasik, Chief Operating Officer of Abundia. “Given Topsoe’s status and reputation within the industry, it should come as no surprise that they continue to deliver on schedule and within budget. We are now advancing the integration of technologies into a comprehensive FEED package. This progress reflects the disciplined execution of our development strategy and brings us another step closer to final investment approval (FIA).”

In March 2026, Abundia announced its partnership with Topsoe, a leading global provider of energy transition technologies, for the deployment of Topsoe’s HydroFlex^® upgrading technology as a key component of its planned Cedar Port facility. Building on that partnership, Abundia is pleased to report Topsoe has met all deliverables due to date, delivering critical engineering materials for its HydroFlex^® upgrading technology including the first issue of piping and instrumentation diagrams (P&IDs), material selection diagrams (MSDs), and equipment lists. Delivery of these materials represents an important advancement in the engineering design package and provides the technical foundation for progressing the full Front-End-Engineering Design (FEED) for Abundia’s integrated technology solution.

The planned 80,000-ton-per-annum facility is being designed to convert waste plastics into high-value, commercial-grade products, including sustainable aviation fuel (SAF), renewable diesel, and naphtha, by combining Alterra Energy’s proprietary plastics liquefaction technology with Topsoe’s HydroFlex^® upgrading platform. The integrated FEED program is being advanced with Burns & McDonnell as FEED engineering partner and Nexus PMG as Owner’s Engineer, providing the engineering foundation for subsequent project execution, procurement, and ultimately, final investment approval.

About Abundia Global Impact Group, Inc.

Abundia Global Impact Group, Inc. (NYSE American: AGIG) is a low-carbon energy company focused on converting waste into value. Headquartered in Houston, Texas, we are developing commercial-scale facilities that transform waste plastics and biomass into drop-in renewable fuels and low-carbon chemical feedstocks. Our flagship project at Cedar Port positions Abundia at the center of the Gulf Coast’s energy and chemical infrastructure, with access to feedstock supply chains, upgrading partners, and end markets.

For more information, please visit www.abundiaimpact.com.

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information generally is accompanied by words such as “believe,” “may,” “will,” “could,” “intend,” “expect,” “plan,” “predict,” “potential” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this press release includes, but is not limited to, statements pertaining to the effects and anticipated effects of the Company’s inclusion in the Russell Microcap® Index. Actual results may differ materially from those indicated by these forward-looking statements as a result of a variety of factors, including, but not limited to: (i) the inherent uncertainties associated with business strategy and ongoing operations, the Company’s current liquidity positions, the Company’s ability to maintain the listing of its common stock on NYSE American, the Company’s ability to predict its rate of growth, and (ii) other risks as set forth from time to time in the Company’s filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond the control of the Company.

With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing the Company’s business is disclosed in our Annual Report on Form 10-K and other filings with the SEC on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Investors:
CORE IR
IR@abundiaglobalimpactgroup.com

Memberships now available to all new and existing customers at $14 per month or $99 per year

Restaurant.com gift cards purchased by businesses now convert directly into membership, extending the Company’s corporate channel into continuing member relationships

Certificates purchased before the transition remain valid and do not expire

SCHAUMBURG, IL, Oct. 29, 2026 (GLOBE NEWSWIRE) — Giftify, Inc. (Nasdaq: GIFT) (the “Company”), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced that Restaurant.com, the nation’s largest restaurant-focused digital deals brand, has completed its transition to a membership-based model, effective October 27, 2026, as previously announced. Restaurant.com Membership is available now at $14 per month or $99 per year.

Active members can now access offers at participating restaurants without purchasing them individually, subject to each restaurant’s offer terms. Memberships are also available to be purchased as a gift.

Restaurant.com gift cards purchased by businesses for customer acquisition, loyalty programs, market research, employee recognition and customer promotions now convert directly into membership. Membership length will be determined by the denomination of the card provided to the recipient and will scale with value.

How businesses purchase is unchanged, but recipients now enter an ongoing membership relationship with Restaurant.com rather than a single transaction. For Giftify, this extends an established corporate channel into the membership base:

• business purchases now originate continuing member relationships;
• recipients receive access for the full membership term rather than a fixed amount of value to spend down; and
• Giftify gains an additional path to membership growth alongside direct consumer subscriptions.

Certificates purchased before the transition are unaffected and do not expire. Customers may continue to use them whether or not they become members or exchange an unused certificate for account points, which apply as a credit toward a membership. Redemption at participating restaurants is unchanged, and no change was required of restaurant partners.

“When we announced this plan, we said Restaurant.com would move to membership on October 27, and it did,” said Ketan Thakker, Chief Executive Officer of Giftify, Inc. “What we find most compelling is what membership does to the business side of Restaurant.com. Companies have been buying Restaurant.com for their customers and employees for years. Those purchases now begin a continuing relationship with a member rather than ending once the value is spent, which is a stronger benefit for our business customers and a different kind of asset for us.”

“Our goal on day one was that nothing our customers already held would be worth less, and nothing our restaurants do at the table would change,” said Thomas Butt, Chief Technology Officer of Giftify, Inc. “Certificates purchased before the transition keep working and do not expire, redemption works the way it always has, and members now have access to the offers at our participating restaurants for as long as they remain members. The transition was completed on schedule using our existing resources.”

Restaurant.com Membership is available now. For more information, visit www.restaurant.com.

About Giftify, Inc.

Giftify, Inc. (NASDAQ: GIFT) is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales from over 1,100 retailers. Restaurant.com is the nation’s largest restaurant-focused digital deals brand, connecting digital consumers, businesses and communities by offering thousands of dining, retail and entertainment deal options nationwide at over 184,000 restaurants and retailers. Takeout7 is a restaurant technology company offering comprehensive online ordering solutions and AI-powered digital marketing services.

For more information, visit: www.giftifyinc.com, www.cardcash.com, www.restaurant.com, and www.takeout7.com.

Forward-Looking Statements

Press releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project,” “propose,” “plan,” “intend,” and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability to identify a suitable business model for the corporation.

Investor Contact:
IR@giftifyinc.com

PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its third quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 11, 2026
Time:	8:30 AM Eastern Time
Conference Call:	https://register-conf.media-server.com/register/BIa693ec3496b1413b8682b952b2ff9e10
Webcast:	https://edge.media-server.com/mmc/p/rsj3o3mw

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.

Participants may join by telephone or webcast using the details below.

Wednesday, November 4, 2026 at 4:30 pm EST
Participant Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID #: 13763480
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=af6qsd3k

A replay of the webcast will be available in the Investors section of the Company’s website at investor.electrocore.com.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore^® non-invasive vagus nerve stimulation (nVNS) and Quell^® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in TJGC Group Limited (Nasdaq: TJGC) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in TJGC from 04:00:00 on October 15, 2026 to 23:59:00 on October 28, 2026. The last sale price of the company’s shares was $31.89. 

More information about the SEC’s order can be found at
https://www.sec.gov/files/litigation/suspensions/2026/34-106668.pdf.

Trading will remain halted until TJGC Group Limited has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SM on the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Contact:

Nasdaq MarketWatch
nasdaqmarketwatch@nasdaq.com

NDAQO

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY^® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com

Dr. Bender brings a proven track record in therapeutic development, company evolution, and strategic execution to help guide Diagonal’s continued pipeline progress

Diagonal is advancing a portfolio of multispecific clustering antibodies that restore normal receptor signaling to enable development of disease-modifying therapies, including DIAG723, currently in a Phase 1/2 clinical trial for Hereditary Hemorrhagic Telangiectasia

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Diagonal Therapeutics, a clinical-stage biopharmaceutical company pioneering multispecific clustering antibodies to address the root causes of serious diseases, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., as Chair of its Board of Directors, succeeding Michael Gladstone, who will continue to serve on the Board. Dr. Bender brings over 20 years of drug development experience and company leadership to Diagonal Therapeutics.

“Jeremy is an accomplished biotechnology leader, who most recently steered Day One Biopharmaceuticals from an early clinical-stage biotech through its first successful commercial launch. We are thrilled to welcome him as Board Chair of Diagonal,” said Alex Lugovskoy, Ph.D., Founder and Chief Executive Officer of Diagonal. “Jeremy’s drug development experience in rare disease, deep operational expertise, and track record across strategic business development will be invaluable as we continue to advance clinical development of our lead program, DIAG723, which represents a potentially transformative, disease-modifying therapeutic for people impacted by hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). We’re extremely grateful to Michael Gladstone for his service as Diagonal’s founding Chair. Michael’s leadership has been fundamental in establishing Diagonal’s position as a leader in clustering antibody technology and driving the significant progress we have achieved across our pipeline. We look forward to his continued contributions as a Board member.”

Diagonal is currently enrolling patients in DIAMOND, a Phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial evaluating DIAG723 in people living with HHT, a rare, serious genetic vascular disorder. The DIAMOND trial will include a multidose Phase 2 cohort (Part C) in people with HHT and concomitant PAH to assess safety and exploratory effects on HHT- and pulmonary-related measures.

“Diagonal’s approach is straightforward and powerful – identify diseases caused by loss-of-function alterations and design antibody therapeutics that seek to activate and restore function through direct binding to altered proteins. This differs from other approaches, which aim to compensate indirectly for loss of function by inhibiting downstream components,” said Dr. Bender. “I look forward to working with Alex, the Diagonal management team, and my fellow board members as we harness this novel science to address the root cause of disease for patients in need.”

Dr. Bender most recently served as Chief Executive Officer, President and a member of the board of directors of Day One Biopharmaceuticals from 2020 to 2026 where he led the company’s evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA^® for pediatric low-grade glioma and the company’s acquisition by Servier in 2026. Before Day One, he served as Vice President of Corporate Development at Gilead Sciences. Earlier in his career, Dr. Bender held executive leadership positions at Tizona Therapeutics (Chief Operating Officer), Sutro Biopharma (Chief Business Officer) and Allos Therapeutics (Vice President of Corporate Development), where he led corporate strategy, business development and operational execution. He began his career in the life sciences practice at Boston Consulting Group. Dr. Bender currently serves on the board of directors of Aura Biosciences, Bicara Therapeutics and Mereo BioPharma Group plc, and previously served on the board of Fusion Pharmaceuticals. He holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

About Diagonal Therapeutics

Diagonal Therapeutics is a clinical-stage biopharmaceutical company pioneering multispecific clustering antibodies, a new class of biologics designed to address the root causes of serious diseases. Our clustering antibodies, derived from our proprietary DIAGONAL Product Engine, are designed to restore normal signaling by assembling receptors in the precise geometry required for activation in diseases that arise from deficient signaling pathways. Our lead product candidate, DIAG723, is a bispecific clustering antibody designed to restore normal activin receptor-like kinase 1 (ALK1) signaling, which is deficient in both hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). For more information, please visit www.diagonaltx.com.

Media Contact:
media@diagonaltx.com

PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced it will report its third quarter 2026 earnings before the market opens on Thursday, November 12th, 2026.

An updated presentation will be posted to the investor relations website concurrent with the earnings release.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: deepisolation.com

Media Contact:
Sophie McCallum
media@deepisolation.com

Investor Contact:
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards; our failure to manage our growth effectively or to execute our business plan; a failure to sustain and expand relationships with governmental entities and strategic partners; failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law. ”

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 14, 2025, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation Nuclear at InvestorRelations@deepisolation.com.

IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Shimmick Corporation (“Shimmick”) (Nasdaq: SHIM), a national leader in complex infrastructure solutions, today announced that the company will release its third quarter 2026 financial results after market close on Thursday, November 12, 2026.

Shimmick will also host a video webcast conference call to discuss those results at 4:30 p.m. Eastern Time on the same day. The conference call will be live-streamed via the Company’s Investor Relations website (https://investors.shimmick.com/). A copy of the earnings call presentation will also be posted to our website.

A replay of the video webcast will be available through the same link following the conference call for a limited time beginning immediately following the call.

About Shimmick Corporation
Shimmick Corporation (NASDAQ: SHIM) is an industry leader in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. The Company integrates technical excellence with collaborative project delivery methods to provide innovative, technology-driven infrastructure solutions that accelerate economic growth and empower communities nationwide. With a track record spanning more than a century, Shimmick combines deep engineering heritage with an entrepreneurial spirit to solve today’s most complex infrastructure challenges. For more information, visit www.shimmick.com.

Contact:         

Investor Relations
+1-949-704-2350
IR@shimmick.com

Media
Lee Ann Ballew
LeeAnn.Ballew@shimmick.com